Avecris
Singapore, Singapore· Est.
Avecris leverages its SPRING DNA platform to deliver scalable, long‑lasting gene‑based medicines without viral vectors.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $60M
AI Company Overview
Avecris leverages its SPRING DNA platform to deliver scalable, long‑lasting gene‑based medicines without viral vectors.
Genetic DiseasesMetabolic DiseasesHematologyOncologyWomen’s HealthImmunologyGastroenterologyOphthalmologyDermatology
Technology Platform
SPRING DNA™ is a non‑viral, programmable DNA vector platform with modular targeting loops and an on/off expression switch, enabling sustained, cell‑type specific protein production.
Opportunities
Scalable, low‑cost non‑viral gene delivery opens large markets in chronic disease therapy and genetic vaccination, especially in regions where viral vector costs are prohibitive.
Risk Factors
Demonstrating in‑vivo efficacy and safety at scale, securing regulatory approval for a novel DNA platform, and competing against established viral and RNA‑based therapies.
Competitive Landscape
Avecris differentiates from viral vectors (e.g., AAV) and mRNA platforms (e.g., Moderna) through its non‑viral DNA approach, offering longer expression, lower immunogenicity, and cheaper manufacturing.